Specific and efficient RNA A-to-I editing through cleavage of an ADAR inhibitor
Nature Biotechnology,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 26, 2025
Язык: Английский
Epitranscriptomics in atherosclerosis: Unraveling RNA modifications, editing and splicing and their implications in vascular disease
Vascular Pharmacology,
Год журнала:
2025,
Номер
159, С. 107496 - 107496
Опубликована: Апрель 14, 2025
Язык: Английский
Harnessing RNA base editing for diverse applications in RNA biology and RNA therapeutics
Advanced Biotechnology,
Год журнала:
2025,
Номер
3(2)
Опубликована: Апрель 8, 2025
Abstract
Recent
advancements
in
molecular
engineering
have
established
RNA-based
technologies
as
powerful
tools
for
both
fundamental
research
and
translational
applications.
Among
the
various
developed,
RNA
base
editing
has
recently
emerged
a
groundbreaking
advancement.
It
primarily
involves
conversion
of
adenosine
(A)
to
inosine
(I)
cytidine
(C)
uridine
(U),
which
are
mediated
by
ADAR
APOBEC
enzymes,
respectively.
been
applied
biological
therapeutic
contexts.
enables
site-directed
within
target
transcripts,
offering
reversible,
dose-dependent
effects,
contrast
permanent
or
heritable
changes
associated
with
DNA
editing.
Additionally,
editing-based
profiling
RNA-binding
protein
(RBP)
binding
sites
facilitates
transcriptome-wide
mapping
RBP-RNA
interactions
specific
tissues
at
single-cell
level.
Furthermore,
sensors
utilized
express
effector
proteins
response
species.
As
continue
evolve,
we
anticipate
that
they
will
significantly
drive
therapeutics,
synthetic
biology,
research.
Язык: Английский
Characterization of RNA editing gene APOBEC3C as a candidate tumor suppressor in prostate cancer
Research Square (Research Square),
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 10, 2025
Abstract
The
human
genome
encodes
19
adenosine
and
cytidine
deaminase
genes,
classified
as
A-to-I
versus
C-to-U
editors.
editors
have
been
widely
identified
a
promising
therapeutic
target
in
various
cancers.
Conversely,
the
investigation
into
is
relatively
limited.
This
study
evaluated
RNA-editing
genes
prostate
cancer
(PCa).
Notably,
APOBEC3
are
clustered
terms
of
their
chromosomal
locations,
transcriptional
changes
exhibit
significant
positive
correlations
both
primary
PCa
castration-resistant
(CRPC).
One
member
this
family,
APOBEC3C,
demonstrated
here
an
androgen
receptor
(AR)-repressed
gene.
Consistently,
loci
epigenetically
inhibited
progression,
with
APOBEC3C
level
lower
PSA-high
patients.
APOBEC3C-low
cohorts
increased
resistance
to
Abiraterone
Enzalutamide.
Clinicopathological
profiling
further
confirmed
downregulation
along
progression
advanced
phases
(grade
IV/V,
stage
III-IV,
pathological
T3-4),
underscoring
its
prognostic
value.
Additionally,
expression
inversely
correlates
relapse
mortality,
low
levels
linked
unfavorable
survival.
integrated
analyses
sole
gene
significance
differential
prognosis,
had
best
diagnostic
performance
among
genes.
Our
efforts
provide
foundation
for
RNA
research
diagnosis
therapy,
grant
candidate
tumor
suppressor.
Язык: Английский
Alpha-1 antitrypsin deficiency-associated liver disease: From understudied disorder to the poster child of genetic medicine
Hepatology Communications,
Год журнала:
2025,
Номер
9(5)
Опубликована: Апрель 14, 2025
Alpha-1
antitrypsin
deficiency
(AATD)
constitutes
an
inborn
disorder
arising
due
to
mutations
in
alpha-1
(AAT),
a
secreted
protease
inhibitor
produced
primarily
hepatocytes.
It
leads
diminished
serum
AAT
levels,
and
this
loss-of-function
predisposes
chronic
obstructive
pulmonary
disease
lung
emphysema.
The
characteristic
Pi*Z
mutation
results
hepatic
Z-AAT
accumulation.
In
its
homozygous
form
(Pi*ZZ
genotype),
it
is
responsible
for
the
majority
of
severe
AATD
cases
can
cause
both
pediatric
adult
liver
disease,
while
heterozygous
(Pi*MZ)
considered
modifier
that
becomes
apparent
presence
other
comorbidities
or
risk
factors.
current
review,
we
collate
conditions
associated
with
AATD,
introduce
typical
variants,
discuss
our
understanding
pathogenesis.
We
present
cross-sectional
longitudinal
data
informing
about
natural
history
noninvasive
tools
be
used
stratification
as
well
basis
monitoring.
Given
AATD-associated
highly
heterogeneous,
factors
affecting
progression.
While
treated
by
weekly
intravenous
administration
purified
AAT,
recombinant
modified
oral
inhibitors
are
currently
clinical
trials.
Among
candidates,
small
interfering
RNA
fazirsiran
efficiently
suppresses
production
phase
3
trial,
several
genetic
approaches,
such
editing,
at
earlier
stages.
summary,
represents
systemic
increasingly
seen
hepatologic
routine
requiring
thorough
interdisciplinary
care,
since
ongoing
trials
often
address
only
one
organs
affects.
Язык: Английский
Characterization of RNA editing gene APOBEC3C as a candidate tumor suppressor in prostate cancer
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Май 22, 2025
The
human
genome
encodes
19
adenosine
and
cytidine
deaminase
genes,
classified
as
A-to-I
versus
C-to-U
editors.
editors
have
been
widely
identified
a
promising
therapeutic
target
in
various
cancers.
Conversely,
the
investigation
into
is
relatively
limited.
This
study
evaluated
RNA-editing
genes
prostate
cancer
(PCa).
Notably,
APOBEC3
are
clustered
terms
of
their
chromosomal
locations,
transcriptional
changes
exhibit
significant
positive
correlations
both
primary
PCa
castration-resistant
(CRPC).
One
member
this
family,
APOBEC3C,
demonstrated
here
an
androgen
receptor
(AR)-repressed
gene.
Consistently,
loci
epigenetically
inhibited
progression,
with
APOBEC3C
level
lower
PSA-high
patients.
APOBEC3C-low
cohorts
increased
resistance
to
Abiraterone
Enzalutamide.
Clinicopathological
profiling
further
confirmed
downregulation
along
progression
advanced
phases
(grade
IV/V,
stage
III-IV,
pathological
T3-4),
underscoring
its
prognostic
value.
Additionally,
expression
inversely
correlates
relapse
mortality,
low
levels
linked
unfavorable
survival.
integrated
analyses
sole
gene
significance
differential
prognosis,
had
best
diagnostic
performance
among
genes.
Our
efforts
provide
foundation
for
RNA
research
diagnosis
therapy,
grant
candidate
tumor
suppressor.
Язык: Английский
Can Proteomics Play a Significant Role in the Identification of Biomarkers for Alpha1-Antitrypsin Deficiency?
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(11), С. 5085 - 5085
Опубликована: Май 26, 2025
Alpha-1
antitrypsin
deficiency
(AATD)
is
a
common
genetic
disorder
that
can
manifest
in
broad
spectrum
of
clinical
symptoms,
ranging
from
asymptomatic
cases
to
severe,
progressive
systemic
diseases,
primarily
affecting
the
lungs
and
liver.
Despite
its
prevalence,
AATD
often
perceived
as
rare
condition,
which
lead
lack
awareness
among
primary
care
physicians
even
some
respiratory
specialists.
This
misconception
may
result
missed
opportunities
for
diagnosis,
particularly
mild
or
patients.
Consequently,
it
vital
healthcare
providers
familiarize
themselves
with
various
presentations,
diagnostic
techniques,
management
strategies
AATD.
review
explores
current
understanding
AATD,
emphasizing
valuable
role
liquid
chromatography-mass
spectrometry
identifying
biomarkers
could
enhance
early
diagnosis
help
predict
disease
outcomes.
As
knowledge
about
complexities
continues
grow,
begin
view
not
fatal
pathology,
but
treatable
inherited
condition
potential
improved
management.
Язык: Английский